It is also being developed for use on all manufacturers machines which would significantly increase the (low-hanging fruit) upgrade opportunity (ICAD's worldwide mammography installed base is ~5k units). ICAD has previously mentioned that preliminary testing has shown much higher performance then they had initially anticipated. Competitive performance could be key relative to maximizing market share among the various manufacturers' installed bases. While timelines to complete development and launch this next-gen product have slipped on a not-irregular basis, ICAD's most recent guidance (on the Q3 call) is largely unchanged from the most recent prior forecast (on the Q2 call in August). Management is shooting to have the product launched in Europe in 1H 2018 and in the U.S. in 2H 2018 - the latter which is contingent on first receiving FDA clearance. Similar to the initial 3D tomo product, U.S. regulatory clearance will be via the PMA pathway and must be supported by a reader study.